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A 33-year-old white man first presented to the Royal Infirmary Stirling,
Scotland, 24 years ago with a history of recent-onset hematuria. Intrave-
nous urography at that time showed a filling defect in the right kidney; a
subsequent aortogram demonstrated a single simple cyst in the right
kidney.
Over the next nine years he suffered from occasional episodes of back
pain, particularly on the right side. His renal tract was further investigated
at the Borders General Hospital 14 years ago because of recurrent urinary
tract infections. His blood pressure at that time ranged from 130/100 mm
Hg to 170/1 10 mm Hg. His hemoglobin was 15.7 mg/dl, with a hematocrit
of 45.6%. Plasma urea and creatinine were normal at 5.1 mmol/liter
(normal, 2.5—6.5 mmol/liter), and 75 jtmol/liter (normal, 55—150 jmol/
liter) respectively. Cystoscopy showed only moderate bladder inflamma-
tion, but a further aortogram at the Royal Infirmary Edinburgh demon-
strated enlarged cystic kidneys bilaterally. The right kidney was
significantly larger and more cystic than the left; a diagnosis of polycystic
kidney disease was made.
Until 11 years ago, the patient's condition was characterized by recur-
rent episodes of back and abdominal pain, but he was able to continue in
his job as a supervisor in a knitwear factory. Cyst aspirations on two
occasions conferred some relief of pain. Eleven years ago, he was admitted
to the Borders General Hospital with acute-onset chest pain. Acute
myocardial infarction was diagnosed on the basis of an increase in cardiac
enzymes and anterior T-wave inversion on the electrocardiogram. His
hemoglobin was 15.6 g/dl. with a hematocrit of 44.7%; his renal function
remained normal. At discharge, therapy with metoprolol, 50 mg twice
daily, and isosorbide mononitrate, 40 mg twice daily, had lowered his
blood pressure to 110/60mm Hg. Because of subsequent episodes of chest
pain, coronary angiography was performed in Edinburgh. The test showed
a dilated left-ventricular cavity with apical hypokinesia and moderate
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left-ventricular function. The right and left anterior descending coronary
arteries were mildly diseased (40%), and a moderately severe stenosis of
the circumflex coronary artery (90%) was present. Continued medical
therapy over the ensuing few months relieved his chest pain. Unfortu-
nately, his abdominal and back pain continued; upper gastrointestinal
tract endoscopy was normal, and an abdominal CT scan confirmed the
presence of polycystic kidney disease with no other organ involvement. His
blood pressure was well controlled by metoprolol and amiloride.
Six years ago he was again admitted to the Borders General Hospital
with an acute right hemiparesis consisting of expressive dysphasia and
weakness of his right arm and leg. His blood pressure and renal function
were normal, but the hemoglobin was 20.4 g/dl with a hematocrit of 60.6%,
and a platelet count of 220 x I 09/liter. Blood urea was 8.5 mmol/liter, and
serum creatinine was 125 /Lmol/liter. A cerebral CT scan, showing an axial
slice at the level of the pineal, disclosed an ill-defined area of reduced
attenuation adjacent to the anterior horn of the left lateral ventricle. No
mass effect was associated with this finding and the scan was compatible
with a recent infarction (Fig. 1). He made a gradual but satisfactory
recovery from his stroke, and regular venesection during the next six
months reduced and subsequently maintained his hemoglobin within the
normal range. Antihypertensive therapy was continued with metoprolol
and amiloride, and aspirin was added to the regimen.
Recurrent back pain continued to dominate his life. As a consequence
of his stroke, his job had been downgraded, and increasingly persistent
pain was threatening his ability to continue in employment. Episodes of
depression responded to medication; intermittent relief continued to be
obtained from cyst puncture and removal of fluid from the right kidney.
The length of the periods of relief gradually decreased, however, and by
last year cyst aspiration was being performed at less than 3-month
intervals. Upper and lower gastrointestinal tract endoscopy were normal.
A CT scan (Fig. 2) of an axial slice at the level of the left renal hilum
disclosed multiple cysts affecting both kidneys, but the left kidney was less
severely affected. Most of the cysts lay anteriorly, and the renal parenchy-
mal tissue was well preserved posteriorly. The scan revealed no other
organ involvement. Analgesia with a range of therapies was unsuccessful.
Because of the continuing pain, he was seen at the Royal Infirmary
Edinburgh late last year for further assessment. He was a 57-year-old
nonsmoker who apart from his back pain (particularly on the right side)
suffered from occasional angina controlled by glyceryl trinitrate spray. He
had a mild expressive dysphasia but no other neurologic deficits. Review
of the family history indicated that his mother had died from a ruptured
cerebral aneurysm at the age of 67 and might have had renal disease. His
father was unknown. He was married with three sons, in one of whom
abdominal ultrasound at the age of 28 had revealed no renal or liver cysts.
The other two sons had declined medical investigation. The patient's
creatinine clearance was 70 mI/mm, and a recent isotope renogram
showed 29% of function on the right and 71% on the left. His hemoglobin
was 16.5 gldl with a hematocrit of 50.4%. Ambulatory blood pressure
monitoring confirmed excellent blood pressure control, although there
was loss of diurnal variation (Fig. 3). A T2 weighted cerebral magnetic
resonance image (MRI) of an axial slice at the level of the bodies of the
lateral ventricles (Fig. 4A) showed a high signal in the ventricles and
cortical sulci. In addition, the MRI revealed focal areas of increased signal
in the left frontal and temporo-parietal regions; these areas corresponded
to areas of gliosis and atrophy secondary to previous infarction. A
magnetic resonance angiogram of the intracranial arterial system (Fig. 4B)
showed a reduction in the size and number of the branches of the left
middle cerebral artery compared with the right. The overall contours of
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Fig. 1. Cerebral CT scan at time of developing a
right hemiparesis.
the vessels were smooth, and no focal irregularities suggested the presence
of an aneurysm.
Further attempts were made at controlling the back pain with analgesia,
but these were unsuccessful. He underwent a laparoseopic right nephrec-
tomy at the Western General Hospital, Edinburgh, early this year with
complete relief of symptoms. The kidney contained many large cysts, some
containing pus. Histologic examination of the fragments of renal tissue
confirmed the presence of polycystic kidney disease. His creatinine
clearance of 65 mI/mm six months later indicated that his renal function
had not changed significantly.
Discussion
DR. MICHAEL L. WATSON (Consultant Physician, Department of
Medicine, Royal Infirmaty of Edinburgh, Edinburgh, Scotland): The
patient presented is instructive because of the number of different
issues raised in relation to management of patients with polycystic
kidney disease and the impact of recent advances in our knowl-
edge of the condition. Although the dominant feature of his
recent clinical course has been progressive, intractable back pain,
the early part of his history relates to the initial diagnosis of
autosomal dominant polycystic kidney disease (ADPKD) and the
subsequent acute cerebrovascular event.
Diagnosis
The ready availability of abdominal ultrasound and CT scan-
ning has transformed our ability to diagnose ADPKD. Cysts,
however, develop at varying rates and in some instances may not
be evident until well into the adult years. For this reason, the usual
criteria employed are that there should be two cysts present in one
kidney and one in the opposite kidney in those patients with a
family history of ADPKD.
Genetic counseling is most valuable if a reliable diagnosis is
possible by the patient's reproductive years. Bear et al estimated
that a positive diagnosis of ADPKD is possible in 68% of gene
carriers under age 30 and 89% over age 30 [ii. Other estimates
based on a comparison of gene linkage analysis and ultrasound
detection in at-risk families suggest that a sensitivity of detection
of 88.5% is possible in individuals under age 30 and 100% in those
who are older [2]. As a result of this high sensitivity of detection,
Ravine et a! suggest a modification of diagnostic criteria on renal
ultrasound in patients known to be at risk for the disease. If a
patient is less than 30 years old, two cysts whether unilateral or
bilateral are sufficient, two cysts in each kidney in the 30- to
59-year-old group, and at least four cysts in each kidney after age
60 [2]. The patient presented is unusual in that only one cyst was
evident on arteriography at age 34, but nine years later he had the
classic appearance of polycystic kidney disease. This delayed
development of cysts might relate to the genotype of his disease.
Cerebral vascular disease
The major concern in any young patient with ADPKD present-
ing with a stroke is subarachnoid hemorrhage. An association
between the two conditions has been known for many years.
Recent data from a population of patients with ADPKD suggest
that 12% of all affected patients died from a neurologic event, 6%
of them from a subarachnoid hemorrhage (mean age, 37 3
years) [3]. Data on the prevalence of unruptured cerebral aneu-
rysms are more difficult to obtain, but will gradually improve as
more widespread screening is undertaken. In a large autopsy
series, unruptured intracranial aneurysms were identified in 4% of
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Fig. 2. Abdominal CT scan showing extensive cyst formation in both kidneys.
patients with ADPKD who died from unrelated causes [4].
Although this rate is higher than that in the general population,
the difference was not significant. Asymptomatic intracranial
aneurysms can be identified with either thin-section CT scanning
or magnetic resonance angiography (MRA). Combined data from
three large prospective studies suggest a prevalence of approxi-
mately 8% in the ADPKD population; this figure doubles in
ADPKD patients who have a family history of intracranial aneu-
rysm [5—7]. Morbidity and mortality after rupture of an aneurysm
are high. In the autopsy series from the Mayo Clinic, mortality six
months after rupture was 55% [41, although in a more selected
European population, overall mortality was 10%, but 43% of
those surviving beyond three months after rupture had severe
neurologic disability [81.
The patient discussed today had no clear evidence that a
ruptured cerebral aneurysm caused his stroke. Subsequent inves-
tigation of his cerebral circulation by MRA was justified, however,
both because of the positive family history and the high risks
associated with the presence of an unruptured cerebral aneurysm.
The most important determinant of whether an aneurysm will
rupture appears to be its size. In a series of otherwise normal
patients with unruptured cerebral aneurysms followed for eight
years, all the ruptures occurred when the aneurysm was greater
than 10 mm in diameter [9]. Similar data are not yet available for
a population of ADPKD patients, but prospective studies are
currently underway.
The annual incidence of rupture in the general population
seems to be much the same whether or not the patient has had a
previous episode of rupture: approximately 1.4% [10]. Similar
observations have been made in a group of ADPKD patients
followed for a mean of eight years after surgical clipping of a
ruptured aneurysm [8]. Followup screening by MRA after an
episode of rupture therefore seems fully justified in this popula-
tion, but the broader issue of the risks and benefits of routine
screening of the cerebral circulation in all patients with ADPKD
remains more controversial [11].
Other potential causes of stroke in today's patient were an
intracerebral hemorrhage or cerebral infarction. Intracerebral
hemorrhage is much more likely if hypertension is present,
accounting for nearly one-half of the deaths from neurologic
events in the Denver series [3], with a significantly higher age at
death (51 3 years) by comparison with deaths from subarach-
noid hemorrhage.
It is perhaps surprising that cerebral emboli are not more
commonly associated with ADPKD. A variety of studies have
indicated a high incidence of cardiac valvular abnormalities, both
in life and at autopsy [3, 12, 13]. The mitral valve is most
commonly affected, with as many as 26% of affected patients
showing evidence of valve prolapse, whereas tricuspid prolapse
was present only in 6%. Interestingly, although there was no
evidence of aortic valve prolapse on two-dimensional echocardi-
ography, there was a significant increase in aortic regurgitation
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compared to controls [13]. Yet little evidence indicates that these
abnormalities are a major cause of death, or that the valve defect
acts as a source of cerebral emboli.
It is highly likely that secondary polycythemia in this patient
contributed to his stroke. Polycythemia is a rare but well-de-
scribed complication of ADPKD [14, 15]. Most likely it relates to
excessive production of erythropoietin [16], probably from inter-
stitial cells adjacent to cysts. It is interesting that after the initial
reduction of his hemoglobin, further increases could be prevented
by comparatively infrequent venesections. From the patient's
perspective, perhaps the most encouraging features of his illness
were the extent of recovery since his stroke and his ability to
continue in a demanding occupation until chronic pain disrupted
his work pattern.
Chronic pain
Chronic intractable pain, at least in the early stages of ADPKD,
is well documented [17]. This patient suffered from loin pain for
18 years although cyst puncture, at least initially, provided long
periods of relief. The value of cyst aspiration in relieving the pain
was clear, but characteristically the relief provided by further cyst
aspirations lasted for shorter and shorter periods [18]. In my
experience, injection of a sclerosing agent such as alcohol, while of
value in the treatment of a single cyst, has not been successful in
ADPKD [19]. For this patient, continued treatment of pain with a
variety of agents was increasingly ineffective. The opiate-based
analgesic led to drowsiness and a restricted ability to work.
No satisfactory studies exist on the best analgesic for use in
patients with ADPKD; the best guidance, therefore, is to follow
the principles used in other forms of chronic pain relief [20]. The
persistence of severe pain in ADPKD is well known [21] and the
complication of associated depression, as in this case, is not
uncommon. Tricylic antidepressants can be useful both as an
antidepressant and as an adjuvant analgesic. Clearly, therapy has
to be tailored to the individual. In this case, the persistent severity
of the pain so disrupted the patient's quality of life that a surgical
approach finally was used to relieve the problem.
Laparoscopic cyst decompression versus nephrectomy
In today's patient, a relatively noninvasive surgical approach
was desirable because of the history of myocardial infarction and
a major cerebral event, although control of blood pressure was
unlikely to be a problem during anesthesia. Surgical decompres-
sion has been used effectively for pain relief [22]; a decline in renal
function following decompression, which has been of concern, is
probably not of great significance [23]. Laparoscopic cyst decom-
pression has been used effectively for treatment of pain [24]. In
our patient, the absence of guidance as to which of the multiple
cysts might be responsible, and the patient's unwillingness to
undergo further cyst decompression (because of his persisting
doubts as to the long-term benefit), led us to choose a complete
laparoscopic nephrectomy. The subsequent finding of infection in
the resected kidney probably contributed to the severity of the
pain. Urinary tract infection is very common in ADPKD, and
infected renal cysts are difficult both to diagnose and treat [25].
Laparoscopic nephrectomy is an established procedure, but its
use for removing a polycystic kidney has not been documented.
The subsequent success of nephrectomy in providing almost
complete symptomatic relief was satisfactory, but there were and
there remain concerns about the effect of nephrectomy on the rate
of decline of renal function in the remaining kidney.
Blood pressure, renal function, and cardiovascular disease
The patient's blood pressure always was easy to control, and his
renal function was reasonably well preserved. I will discuss the
implication of these findings in relation to the underlying gene
defect later. Part of the reason for the relative ease of blood
pressure control might have been the myocardial infarction 10
years previously, but other factors such as the presence of large
kidneys [26] suggest that hypertension could have been more of a
Fig. 4. A. Cerebral magnetic resonance imaging
five years after cerebral infarction. B. Cerebra!
magnetic resonance angiogram.
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problem. The importance of hypertension relates both to the
acceleration of renal impairment and also to progression of
concomitant vascular disease. Hypertension develops very early in
the course of ADPKD; significant increases are evident by ado-
lescence [27], with a subsequent progressive rise with age [28].
The early rise in blood pressure correlates with the presence of
target organ damage in the form of left-ventricular hypertrophy
[27]. A significant factor contributing to the development of target
organ damage also might be an increased "blood pressure load"
over 24 hours as a consequence of the loss of the usual nocturnal
fall in blood pressure [29] or an elevation in nocturnal pressure
[271. Although overall blood pressure control was very good in this
patient, he did have a loss of diurnal variation of blood pressure
in the 24-hour recording. The extent to which good blood pressure
control in this patient has delayed the progression of renal failure
must be speculative. It is disappointing, however, that the studies
available to date in patients with ADPKD do not show any value
of tight control of blood pressure, at least over a relatively short
time period (2 years) in patients with established renal failure
[30].
Much of the focus of blood pressure research has been in
relation to preservation of renal function, but as survival with
dialysis and after transplantation improves, broader issues
emerge. This patient had significant atherosclerotic vascular dis-
ease at an early age that led to myocardial infarction and probably
cerebrovascular disease. While these events might reflect only the
high incidence of atherosclerotic vascular disease in the Scottish
population, evidence suggests acceleration of vascular disease in
ADPKD [3, 31—33]. The extent to which a long-standing modest
elevation in blood pressure contributes to vascular disease is
unclear, but it does emphasize the importance of considering
delayed progression of generalized vascular and particularly cor-
onary artery disease as one of the potential benefits of good blood
pressure control.
End-stage renal failure is reached more rapidly in males
affected with ADPKD than in females [34], with a mean age of
reaching dialysis of 52.5 years in males and 58.1 years in females.
Recent clarification of genetic heterogeneity does indicate, how-
ever, a separate group of patients (type-2 disease) in which
progression to end-stage renal failure is delayed, and hypertension
is less severe [35]. Knowledge of the individual genotype of
patients therefore will assist in providing a firmer basis on which
to judge their prognosis. I'll return to this issue shortly.
In the patient we are discussing, the clinical desirability of
removing the right kidney to control pain had to be tempered by
the potential for more rapid progression to end-stage renal
failure. Not only was a small, albeit significant, amount of
functioning renal tissue being removed, but also the possibility
existed that the removal of one kidney might, as a consequence of
glomerular hyperperfusion, accelerate the decline in renal func-
tion of the remaining kidney. Reassurance was gained from the
collaborative study by Zeier and colleagues, who demonstrated
that the rate of decline of renal function after uninephrectomy in
ADPKD did not differ significantly from the rate of decline of
renal function in patients with two kidneys [361. In this case, the
right kidney provided only 29% of function, giving an estimated
glomerular filtration rate (from creatinine clearance) of 41 ml/min
in the left kidney. In fact, measurement of creatinine clearance six
months post nephrectomy suggested that the renal function had
not significantly declined further. Uninephrectomy has been
reported to exacerbate hypertension [36], but in this case the
hypertension was not difficult to treat and renal function, at least
in the residual kidney, was well preserved.
Genetics
In comparison with many affected individuals, this patient has
had a relatively benign course with respect to the decline in renal
function and severity of hypertension. Before we examine these
phenotypic variations, it is perhaps worth considering the genetic
defect responsible for ADPKD and the way in which improved
understanding of this defect will in due course allow better
characterization of patients.
Although the pattern of inheritance of ADPKD was described
many years ago [37], the identification of linkage between alpha
globin and ADPKD located the gene defect on the short arm of
chromosome 16 [38] and led to an explosion in investigative work.
Initial studies of gene linkage in families failed to detect evidence
of heterogeneity [391, but as more families were studied, hetero-
geneity was confirmed, and further linkage analysis studies have
led to the localization of a second gene (type-2 disease) to
chromosome 4 [40—43]. The relative prevalence of type-i versus
type-2 disease is approximately 85% to 15%, but a paucity of
families with type-2 disease has restricted an understanding of its
clinical significance. Increasing evidence suggests that type-2
disease has a better prognosis than type-i, particularly with regard
to development of end-stage renal failure [35]. Appearance of the
kidneys on ultrasound examination is similar, although more
extensive cyst development often occurs in type-i. Therefore,
without genetic studies, identification of patients with type-2
disease must be speculative. In today's patient, the late develop-
ment of cysts, the mild hypertension, and the relative preservation
of renal function favor type-2 disease, as does the absence of renal
failure in the known affected relative. Confirmation of the pres-
ence of type-2 disease requires a larger pedigree for analysis than
was available in this instance. In practice, genetic testing in a
family such as this must await the delineation of mutations in the
relevant genes that can then be identified in affected individuals.
Recent identification of other pedigrees unlinked to either the
type-i or type-2 locus raises the possibility of yet further genetic
heterogeneity (type-3 disease) [44].
Because of technical difficulties, it has taken almost 10 years to
clone and sequence the type-i ADPKD gene since its initial
localization to the short arm of chromosome 16. It is a large,
complex gene with large regions of the gene being reiterated three
times elsewhere on the same chromosome— homologous gene
areas. Whether these other genes code for specific proteins is not
yet known. The presence of the homologous gene areas has
caused considerable confusion when researchers have attempted
to isolate cDNA relating to the ADPKD gene alone [45, 461. The
crucial breakthrough in isolating the gene came with the identi-
fication of a family with tuberous sclerosis type II (TSCII) and
polycystic kidney disease [471. Polycystic kidneys have been de-
scribed both in tuberous sclerosis type I and type II [48]. Because
TSCII and ADPKD are linked to loci on the C16 chromosome, a
causative link between the two has been suggested [49], but renal
cysts also occur in patients with TSCI, which is linked to chromo-
some 9 [50]; this finding makes such a direct relationship unlikely.
Using a positional cloning strategy, the European Chromosome
16 Tuberous Sclerosis Consortium identified the gene for TSCII
on chromosome 16 [51]. One particular family from Portugal,
Nephrology Fomm: Complications of ADPKD 359
Fig. 5. Predicted molecular structure of
polycystin (from Ref 46).
however, had a pedigree in which different family members
exhibited one or both of the typical phenotypes of ADPKD and
TSC. Family members in two generations showed a 16:22 bal-
anced chromosome translocation; both these individuals had
ADPKD. The break point for the translocation on chromosome
16 was localized within l6pi3.3 (the area known to contain the
PKD1 gene), and the gene disrupted was labeled the polycystic
break point gene (PBP). In another family member, the translo-
cated section of l6pl3.3 l6pter was deleted, resulting in TSCII.
This finding confirmed the extremely close proximity of the PBP
and TSCII genes. The PBP gene is in fact the PKD1 gene [47].
A number of point mutations or small deletions have been
identified in the type-i gene, but because of the technical diffi-
culties associated with eliminating the homologous gene se-
quences, all these are located towards the 3' end of the gene [46,
52]. To date, the mutations identified account for only a small
number of the presumed mutations in affected families. The
ADPKD 1 gene is large, containing 14,148 base pairs divided into
46 exons. Thus it is possible that some of the mutations identified
to date merely represent polymorphisms that do not significantly
disrupt the normal functioning of the gene. It also is possible that
some mutations lead to only a partial loss of gene function and a
relatively mild phenotype, whereas complete deletion of the gene,
as seen in certain infantile cases of ADPKD associated with
TSCTI, leads to a very severe form of cystic kidney disease [53]. It
seems likely that large numbers of mutations remain to be
identified and probably will reflect a relatively high new mutation
rate.
Cloning of the PKD1 gene rapidly led to detailed nucleotide
sequencing and prediction of the protein structure. Very similar
results were reported by independently operating groups [45, 46,
54]. The PKD1 protein has 4302 amino-acid-containing sequences
that have characteristic functions in other known proteins (Fig. 5).
The two leucine-rich repeat sequences close to the 5' end are
placed between cysteine-rich flanking regions. This placement is
characteristic of proteins in extracellular locations involved in
NH2 kL
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protein-protein interactions, such as cell recognition, signal trans-
duction, or binding to components of the extracellular matrix [55].
The type C lectin domain probably binds carbohydrates in the
presence of Ca permitting interaction with other glycoproteins
involved in cell recognition and adhesion functions [561. The
immunoglobulin-like repeat sequences and fibronectin Ill-related
domain reported by Hughes et a! [46] differs slightly from the
sequences reported by the International Consortium [451. Differ-
ences in the reported length of the transmembrane domain also
make it difficult for us to be sure whether polycystin is totally
extracellular or membrane bound. The charged residues in the
C-terminal end would certainly be consistent with a cytoplasmic
terminus. Whatever its exact function, polycystin likely plays an
important role in the interaction between tubular epithelial cells
and the basement membrane.
A number of different groups have raised antibodies to poly-
cystin. Because of the difficulty of the homologous gene se-
quences, however, all these antibodies are related to the C-
terminal end of the molecule. Polycystin is expressed in renal
tissue early in fetal development, but results vary regarding the
exact location within the kidney, particularly whether expression is
restricted to the distal tubular epithelial cells or present in the
glomerulus and proximal tubule [57, 581.
Recent cloning of the PKD2 gene has provided further insights
into the complex role played by membrane proteins in the genesis
of polycystic kidney disease [591. Flanking markers for PKD2 gene
were first reported in 1993 [42, 43]. The genetic interval subse-
quently has been further refined by identification of other poly-
morphic markers, allowing the construction of a contig of approx-
imately 680 kb spanning the region of interest. A candidate gene
that was expressed in most adult and fetal tissues was isolated
from this region. Moreover, analysis of potential reading frames
demonstrated homology to significant proportions of the amino
acid sequences with those in polycystin. Confirmation that this site
is likely to be the PKD2 gene came from analysis of three separate
type-2 families in which each affected individual was heterozygous
for a single base pair change resulting in a nonsense mutation.
The as-yet-unnamed putative translation product is a protein
with 968 amino acids; approximately 25% of the sequence is
identical with polycystin and 50% is similar. Many of these
similarities are in the transmembrane region, indicating a similar
role as a membrane protein. Significant homology also exists
between other regions of the PKD2 protein and a family of
voltage-activated calcium and sodiuma1 channel proteins.
The authors speculate that PKD2 protein and polycystin function
in parallel, perhaps as a common signal transduction pathway.
These extraordinary genetic advances are set to transform
knowledge of the pathophysiology of PKD. Mutational analysis of
PKD2 families will be rapid, whilst other advances are likely to
overcome the confounding problems of the homologous gene
sequences in detecting PKD1 mutations. The impact of these
advances on the practice of nephrology will be significant.
Questions and answers
DR. JOHN T. HARRINGTON (Dean ad interim, Tufts University
School of Medicine, Boston, Massachusetts): Thank you very much,
Dr. Watson, for a superb review of some of the complications of
polycystic kidney disease and for updating us on the genetics of
PKD. We have several individuals in the audience who are quite
knowledgeable about polycystic kidney disease and I hope they
will participate in our question and answer period. Let me start by
asking a question about the definition. I believe you defined PKD
clinically as at least two cysts in one kidney and one cyst in the
opposite kidney. Yet you also said that we need to distinguish
patients with true PKD from patients with multiple benign cysts
who do not have polycystic kidney disease. In the absence of
genetic analysis, how does one manage that feat?
DR. WATSON: It can be difficult. The definition that you have
given is satisfactory if there is a family history of ADPKD. If there
is no family history, it is still relatively straightforward if there is
widespread renal involvement with multiple cysts, but in milder
forms, differentiation from simple renal cystic disease can be
difficult. David Ravine's data do give some guidance by building in
a correction for increased number of simple cysts that occur with
age [2]. Therefore, by age 60, the requirement for diagnosis is four
cysts in each kidney. With some cases, however, diagnosis can be
difficult, and to some extent relies on the subjective impression of
the radiologist. An additional problem is that cysts may develop
more slowly in type-2 disease.
DR. HARRINOTON: Are there studies on the use of angiotensin
converting enzyme inhibitors in patients with polycystic kidney
disease and hypertension? We finally have evidence that ACE
inhibitors delay the progression of renal disease in diabetic renal
disease [60]. Are similar data available in patients with polycystic
kidney disease?
DR. WATSON: Angiotensin-converting-enzyme inhibitors lower
renal vascular resistance in patients with ADPKD and therefore
might have beneficial effects in managing hypertension and pre-
serving renal function [61, 62]. A long-term prospective study is
currently underway in Europe to try to determine their value early
in the course of the disease. Unfortunately, it will be some years
before the results are available.
DR. YVES PIRsON (Cliniques Universitaires Saint-Luc, Brussels,
Belgium): Congratulations on your interesting discussion covering
many aspects of polycystic kidney disease. I also have a question
relating to the management of hypertension. In view of the
relative polycythemia, wouldn't an ACE inhibitor have been a
better choice of antihypertensive than a diuretic?
DR. WATSON: I agree. I think first-line therapy for most patients
with ADPKD would be an ACE inhibitor, a beta blocker, or a
calcium antagonist, and this is particularly true in the presence of
polycythemia.
DR. PIRSON: Could you comment on the disappointing results of
the MDRD study in the United States regarding the management
of hypertension?
DR. WATSON: The Modification of Diet in Renal Disease Study
focused on patients who already had significant renal damage and
whose glomerular filtration rate was 25—55 mllmin/l.73 m2 [30].
Stringent blood pressure control and protein restriction appeared
not to confer any advantage so far as limiting the rate of decline
of renal function, when compared to patients managed with
conventional blood pressure control and protein restriction. This
result is disappointing, but it is worth emphasizing that most of the
patients had significant renal impairment. We are particularly
curious as to whether stringent blood pressure control provides
benefits when begun very early in the course of disease, before
impairment of renal function is detectable.
DR. EBERHARD RITZ (Klinikum der Universitat Heidelberg, Hei-
delberg, Germany): I would like to add an additional comment to
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Dr. Watson's response. The MDRD study compared two regi-
mens for controlling blood pressure. One was regarded as having
acceptable clinical levels for blood pressure control in patients
with renal disease (mean BP < 107 mm Hg in patients age 18—60)
and the other a regimen that aimed to achieve stringent blood
pressure control (mean BP < 92 mm Hg). What the study did not
demonstrate was that blood pressure wasn't important in renal
disease, but merely that stringent blood pressure control in
patients with renal impairment did not confer an added advan-
tage. The clinical imperative of satisfactory blood pressure control
in patients with renal impairment remains.
DR. HARRINGTON: The cerebral MRA study was negative in this
individual. Is there a higher false-negative rate if one compares
MRA with conventional cerebral arteriography for the detection
of cerebral aneurysms?
DR. WATSON: Dr. Allan, perhaps you would respond to that
question.
DR. PAUL ALLAN (Consultant Radiologist, Royal Infirmaiy, Ed-
inburgh, Scotland): Magnetic resonance angiography is coming
along very nicely, but I don't think it is yet as good as digital
radiographic images. Proponents of MRA say it's wonderful; I
think the people who tend to be a little more objective about it
would say that for some small aneurysms, less than about 3 mm in
diameter, there is a significant risk of missing them with MRA.
DR. HARRINGTON: I have a followup question regarding MRA.
In a patient like this, who had a major cerebral event and a
negative MRA, should one proceed with conventional cerebral
arteriography?
DR. ALLAN: The event on CT scan of the brain in this patient
was typical of a thrombotic event rather than a hemorrhagic event.
The clinical picture and the CT scan were not that suggestive of a
subarachnoid hemorrhage, so I think probably in this case, no.
Had there been the least suggestion that this patient had suffered
a subarachnoid hemorrhage, but had a negative MRA, then it
would be mandatory for us to do a conventional angiogram.
DR. ALEX DAVISON (Consultant Renal Physician, St. James's
Hospital, Leeds, UK): This patient seems to be very unusual in
that cysts totally destroyed one kidney and appear to involve just
the anterior half of the left kidney, with quite a lot of normal-
looking kidney behind it. How often do you see that sort of
disparity in the distribution of cysts?
DR. ALLAN: Not that often. I believe that it would be most
unusual to see this appearance in a 58-year-old patient with type-i
PKD. One of the reasons we chose this patient was precisely
because of his unusual presentation, and because his renal
function was relatively well maintained by the residual cortex.
Normally it is a diffuse field change throughout the kidneys, and to
see such a significant portion of normal kidney is, in my experi-
ence, rare in this age group.
DR. DAvISoN: I have two questions that relate to the surgery.
First, I found it interesting that you removed the kidney laparo-
scopically instead of with a more conventional approach. Second,
was this specimen examined histologically to see whether there
was malignant change in any of the cysts?
DR. WATSON: Perhaps it would be best if we asked the surgeon
to respond to your question.
DR. DAVID TOLLEY (Consultant Urologist, Western General Hos-
pita4 Edinburgh): Thank you. First let me answer Dr. Davison's
question about the pathology. Certainly it was an unusual kidney
in that many of the cysts were full of infected fluid and were not
full of blood as we so often see. In retrospect, I think that a lot of
this man's pain was due to recurrent infection. There was no
evidence of malignant change.
Now I will comment on some of the surgical aspects of this case.
Our considerable experience with laparoscopic nephrectomy in
Edinburgh confirms that this is a good and safe technique for
patients with benign renal disease. A comparison of some 60
patients undergoing laparoscopic nephrectomy with a contempo-
rary series of patients undergoing standard nephrectomy demon-
strated that blood transfusion requirements and duration of
hospital stay were significantly lower in the laparoscopic group
[631. Postoperative morbidity is reduced and the procedure is safe.
In our hands, these benefits are at the expense of a minimally
increased operating time of some 15 minutes. We believe, how-
ever, that the benefits to the patients who have a laparoscopic
procedure are so great that the brief increase in operating time is
of little or no significance. The difficulties in performing laparo-
scopic nephrectomy for polycystic disease relates largely to the
size of the kidney and its subsequent removal. The cysts often
obscure the renal pedicle, and thus it is necessary to puncture a
number of cysts around the hilum to identify the vessels clearly.
Having completed the dissection, one must then place the grossly
enlarged kidney in an impermeable sac and then morselate the
kidney whilst it remains in the sac, removing portions of the
kidney piecemeal. The worldwide experience of laparoscopic
nephrectomy for polycystic disease is limited to a handful of cases,
but our experience with laparoscopic nephrectomy compares
favorably with that reported in the literature and, in experienced
hands, this technique offers significant advantages over conven-
tional surgery [641.
DR. HARRINGTON: It seems that there was significant infection
in a number of cysts. What techniques are available to identify cyst
fluid, hemorrhage, or infection in cysts?
DR. WATSON: It is very difficult to detect infected material. Dr.
Allan could comment on the scanning appearances, but I think it
difficult to detect infection other than by direct aspiration, sys-
temic features of infection, or both.
DR. ALLAN: It has been a great problem over the years, and my
heart always sinks when I am sent a patient with polycystic kidney
disease, because finding infection or hemorrhage is very difficult.
Occasionally we identify on ultrasound a particular cyst that has
increased echoes within it; we then put a needle into it and get
back pus or blood, but echogenic cysts can have debris in them
from previous episodes of infection. Quite often you can become
disoriented; some of these large kidneys can be 22 cm long by 10
to 12 cm wide, and the ultrasound image does not reveal the whole
kidney. I think we will probably look to MRI scanning in the
future for these patients. Based on my anecdotal experience of
two cases, I think that this technique has the potential to identify
cysts with different fluid consistencies within them. One patient
had apparently normal cystic appearances on CT and ultrasound.
But an MRI scan on one of our old machines, a very low field
strength machine, showed a cyst with fluid in it that we were able
to identify on ultrasound and aspirate with a 20 gauge needle. I
think that the development of MR1 techniques offers great
potential for our being able to distinguish an old from a recent
hemorrhage and to identify the fluid in a cyst without pus or blood
in it.
DR. LIAM PLANT (Royal Infirmaty, Edinburgh): The literature
contains quite a few studies from in-vitro systems on the transfer
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of different types of antibiotics into cysts [25]. The suggestion has
been made that aminoglycosides and penicillins concentrate
poorly in some types of cysts and that quinolones perhaps do so
better. Is there a clinical advantage to using antibiotics of that type
in trying to eradicate infection?
DR. WATSON: In my experience, no. I couldn't say that there is
an advantage either way. Most of the data from the literature rely
on measuring antibiotic penetration in cyst models. I don't know
of any clinical studies that have looked at the outcome of
treatment of cyst infection with different antibiotic regimes.
DR. PLANT: Do you think ambulatory blood pressure monitor-
ing should become standard clinical practice in light of the
increased risk of end-organ hypertensive damage in these pa-
tients?
DR. WATSON: I am very impressed by the value of 24-hour
ambulatory blood pressure monitoring for providing a much
better assessment of overall blood pressure control. I think that
quite often the random clinic pressures that we obtain do not give
a clear picture. Questions remain about the significance of the
lack of diurnal variation of blood pressure, and we are trying to
obtain better evidence as to whether good control of nocturnal
blood pressure assists in delaying progression of the complications
of the disease. Clearly these would be difficult long-term studies,
but in the meantime I think there is every clinical justification for
trying to achieve smooth blood pressure control throughout a
24-hour period.
DR. HARRINUTON: What have we learned about the fundamen-
tal reason for the progression of polycystic kidney disease? I was
taught many years ago that it might be cyst enlargement, that it
might be interstitial damage, that it might be hypertension, and
that it might be infection. Well, it's 30 years later and I still have
all of these "might be's." What do we know now about the causes
of progression of PKD beyond hypertension and infection?
DR. WATSON: Three main mechanisms apparently are involved
in the progression of damage. Unfortunately, our knowledge of
the relative contribution of each of these mechanisms remains
poor. They are: epithelial cell proliferation, cyst fluid accumula-
tion, and interstitial damage. Although the relationship among
these three factors remains unclear, it can only be a matter of time
before the recent work on polycystin and its role in membrane
function and interaction with the interstitium will provide us with
better answers about the underlying pathologic process.
DR. CHRISTOPHER IsLEs (Dumfries and Galloway Hospital, Scot-
land): How often do you see this rapid progression from someone
who at 34 has one simple cyst and then nine years later has
extensive bilateral polycystic kidney disease?
DR. WArsoN: I think this is really unusual, and that is part of the
reason why we presented the case. The possibility remains that
some of the cysts weren't identified by arteriography because of
the relative insensitivity of this technique for finding cysts, but it
does seem remarkable that there was such an obvious progression
over a relatively short period.
DR. IsLEs: In that case, does this individual fall into a particular
category or is he a "one-off" patient?
DR. WATSON: I think he more closely fits into a type-2 PKD
category. The relatively low level of blood pressure, the preserved
renal function, and the late development of cysts all point to
type-2 PKD. Cases such as this demonstrate the potential value of
a clear definition of the mutations in type-i and type-2 so patients
can be correctly categorized and counseled about prognosis.
DR. ALLAN: It is worth emphasizing that intravenous urography
and arteriography will show large cysts but will not show small
developing cysts that are not yet big enough to distort either the
vessels or the pelvicalyceal system. These examinations are fairly
crude tests that have been supplemented by the more sensitive
ultrasound and CT scans. It may well be that at the time of his
original arteriogram, this patient did not have just a single cyst but
in fact had one dominant single cyst and several smaller ones that
were too small to be seen with these relatively crude diagnostic
techniques.
DR. ISLES: I still feel a bit uncomfortable about diagnosing this
condition in, say, someone with three cysts and normal renal
function with no family history.
DR. WATSON: I agree with your sentiments, but I think that in
the absence of satisfactory genetic information, this is when one
has to rely on the subjective opinion of the radiologists.
DR. HARRINGTON: I alluded to this question earlier. Should we
be doing genetic analysis in all these patients rather than trying to
hazard a diagnosis on the basis of ultrasonography?
DR. ALLAN WRIGHT (Western General Hospital, Edinburgh):
Mutational analysis is a major problem with the PKD1 gene for a
number of reasons. First, the gene is unusually large. The coding
regions of most genes cover 1000—2000 nucleotide base pairs (1—2
kb) of DNA; the PKD1 gene is 14kb long. Second, the coding
regions are broken up into 46 exons, each separated by large
non-coding or intronic regions. What one would normally do to
look for mutations would be to analyze the exons in turn using
DNA primers flanking each exon. There is a rather simple
technique called single-stranded conformational polymorphism
(SSCP), which is suitable for mutation screening in small exons.
The gene from Marfan's syndrome, fibrillin, is another large gene
that can be conveniently analyzed in this way, except that it is a big
job, since there are also many exons.
In the case of PKD1, there is a further complication. Because of
the homologous gene areas, about 60% of the gene is duplicated
elsewhere on chromosome 16. There are two or three copies in
distinct genes at other sites on chromosome 16. These other
regions are so homologous with PKDI that it is currently impos-
sible to distinguish which gene you are looking at when analyzing
the exons that are duplicated.
The second approach, which is probably more promising, is
analyzing the gene as a whole from a fresh blood sample. This is
possible because even a low level of transcription of PKD1 within
blood cells is detectable by polymerase chain reaction (PCR)
amplification. The advantage of this technique is that the reverse
transcribed/PCR amplified gene detected in blood is fully spliced
with no intervening sequences remaining. However, it is still a
major problem to analyze this gene for mutations because of the
strong homology to other genes.
If mutation analysis cannot help with early diagnosis, what
other approaches can be used? One is the conventional linkage
approach. Generally this method requires the availability of at
least two affected family members for sampling. The patient
discussed did not have this setting, although it is possible that
archival material on the presumed carrier relative who died—his
mother—might solve the problem and make it possible to exclude
chromosome 16 by linkage. Of course, this is a much easier
analysis to carry out. It does raise the question, what is the current
clinical relevance of isolating the PKD1 gene? Within a reason-
able period of time, it might be possible to have specific primers
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that can distinguish the true PKD1 from homologous genes and
allow conventional mutation analysis. This advance in turn might
give information on prognosis in the individual patient, since
particular mutations may be associated either with a mild disease
or a severe, early-onset condition. Such an advance might have
implications for patients considering predictive testing and poten-
tial termination of affected pregnancies. In the case of this
particular family, the disease is relatively mild, so termination
would probably be inappropriate. Even in families segregating for
severe, type-i disease, however, most individuals decline prenatal
diagnosis [65, 661. I suppose it boils down to the fact that
DNA-based prediction could be useful in establishing the prog-
nosis for the three sons who are at risk of developing the disease.
This information might help with their management, but the real
value of genetics is yet to come, when we find out more about the
function of the PKD1 gene and new ways of treating PKD1
patients.
DR. JOHN DONOHOE (Consultant Nephrologist, Beaumont Hos-
pita4 Dublin, Ireland): I would like to ask one further question in
relation to imaging and diagnosis of polycystic kidney disease.
What added diagnostic value is the presence on ultrasound of liver
and/or pancreatic cysts?
DR. ALLAN: If you have, say, a 45-year-old patient with a few
cysts in a kidney who has liver cysts as well, then you are well on
the way to making the diagnosis. I think the whole question about
diagnosis and definition is very difficult; the last thing you want to
do is label someone as having polycystic kidney disease when they
do not. We try to be very cautious. A 1983 study on the incidence
of simple cysts in patients who were having CT scans for nonrenal
disorders showed that having more than one simple renal cyst was
very unusual in patients under the age of 40 [67]. I think that the
presence of cysts in the liver does add more diagnostic weight than
do cysts in other organs such as the pancreas.
DR. R, BERND STERZEL (Universitat Erlangen-Nurnberg, Erlan-
gen, Germany): There remains the clinical problem of what can be
done to help these patients. Years ago, cyst puncture or surgical
"deroofing" was a popular technique. This approach fell out of
favor, particularly the aggressive surgical techniques, because of a
suggestion that they may have either caused a deterioration in
renal function or, at best, yielded no significant improvement.
Have the advent of laparoscopic techniques and the ability to
identify cysts more accurately changed this opinion, and should
selective cyst aspiration be more widely used in the future?
DR. TOLLEY: We are often called upon to perform nephrectomy
for patients with unremitting pain from polycystic kidneys. There
are the problems of operating on patients with polycystic renal
disease and also the subsidiary issue of laparoscopic nephrectomy.
The major problems we face as surgeons are being asked to
deroof or decompress cysts and to identify which of the cysts are
symptomatic and therefore require decompression. Laparoscopy
is an all-too-convenient and easy way of examining the kidney;
therefore the temptation to intervene surgically is perhaps much
greater than it was four or five years ago. For so! italy cysts we still
recommend a relatively conservative approach with cyst aspiration
and sclerosing therapy. If this fails, laparoscopic partial excision of
the cyst wall is an effective treatment. However, it is difficult to
adapt this technique for the patient with polycystic renal disease
because of the difficulties of specifically identifying the cyst or
cysts responsible for the patient's symptoms.
DR. ALLAN: Could I make a comment on aspirating cysts? One
of the reasons for aspiration, other than hemorrhage or infection,
is pain and discomfort. The reason for the pain and discomfort is
the stretching and pressure on the renal capsule. The problem
about polycystic kidneys and also polycystic livers is that the cysts
are almost "alive," and if you take one away you disturb the very
fine balance of pressures and counterbalances present in the
kidney. Then another cyst will enlarge over a period of a week or
so to replace the missing volume; eventually you have quite a
difficult problem. You end up putting needles into four, five, or six
cysts and hoping that you are taking away enough mass to produce
pain relief.
DR. RITz: I notice that two of the offspring refuse to have
screening. What do you think is the importance of screening, and
is there a price to be paid once the relatives have been screened?
For instance, what would screening do to their insurance?
DR. WATSON: I think there are major ethical issues involved in
screening, and these are likely to be increasingly important. In the
absence of a specific clinical indication, it is doubtful whether
patients should be screened before age 18. If a child from an
affected family develops a symptom that could be a consequence
of ADPKD, such as loin pain, urinary tract infection, or severe
headache, screening can be justified, because our knowledge as to
whether the patient is affected can significantly influence clinical
management. In the absence of such symptoms, it is better to
undertake screening with the informed consent of the individual,
that is, ideally after the age of 18. The difficulty arises in relation
to blood pressure and, to a lesser extent, renal function. We know
from Heidelberg data that increases in left-ventricular mass index
are already evident in affected adolescents [271; this finding
suggests that early treatment of even mild hypertension is appro-
priate. Alternatively, all the children of affected families should
have their blood pressure and renal function checked at perhaps
two-year intervals to allow early intervention. The key factor in
favor of screening is whether effective therapy is available that can
significantly alter the course of the disease in young affected
individuals. We cannot yet answer this question.
The reasons against screening relate more to the moral ques-
tion of the importance of individuals being able to make their own
decisions about screening. Clear negative implications exist in
relation to insurance ratings and job applications for affected
individuals. If patients are faced with a fait accompli because of
screening at their parents' or physician's behest early in life, they
may well harbor significant anger at the penalties suffered in adult
life.
We also should consider genetic counseling and its implications
for parenting. Most physicians would advise that individuals be
screened before marriage, particularly so that the unaffected
spouse can be made aware of the implications for the future.
Effective counseling requires significant patient education, be-
cause it is clear that most individuals, despite substantial family
experience, have little understanding of the condition [66]. A
program of education for potentially affected individuals is a
prerequisite and should be undertaken, at least in part, before
screening to allow the patient to make an informed decision.
There has been little demand to date for prenatal screening.
Although many parents wish to know whether their child is
affected, few would opt for termination of pregnancy on the basis
of a positive result. The same is probably not true for the recessive
form of cystic kidney disease [68].
DR. BRIAN JUNOR (Western Infirmary, Glasgow, Scotland): Could
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I comment on the rate of decline of renal function in males versus
females? In the Denver study [261, the lines of the rate of decline
in each group are almost parallel, yet males overall have a higher
incidence of renal failure at a younger age than females. This
observation suggests that the decline starts earlier in males than
females, but that the actual rate of decline is comparable. Could
you comment on this?
DR. WATSON: Yes, the slope of the line for declining renal
function in the Denver data is very similar for the two sexes [26],
but presumably the entry point is different. The difficulty, of
course, is obtaining accurate data on the early phase of decline in
function in each group.
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